The Zantac Recall: A Timeline

Zantac Recall

The Food and Drug Administration (FDA) has recalled Zantac and other heartburn drugs containing the active ingredient ranitidine. This is due to alleged high levels of NDMA, a known carcinogen, forming in the packaging and also breaking down in the body.

The latest market-level recall may have seemed to come out of nowhere, but looking into the matter further shows recalls and warning that go back to September of 2019.

The Latest Zantac Recall and Lawsuits

On April 1, 2020, the FDA issued a market-level recall of ranitidine-based heartburn medication, including name-brand Zantac.

This recall includes both over-the-counter (OTC) and prescription versions of the drug at all strength levels. This means that all ranitidine products are unavailable for new prescriptions and are being removed from shelves.

It is highly recommended that you properly dispose of Zantac in your household.

Because of this recall and the alleged cancers that are ensuing from the use of Zantac, the number of lawsuits is on the rise.

If you have been diagnosed with cancer after prolonged usage of Zantac or another ranitidine-based medication, you may qualify to participate in the mass tort.

Please fill out our pre-qualification form to see if you are able to file a lawsuit through VanDerGinst Law in this matter.

Early Zantac Recall

Going back to the beginning on the recalls, we see little cause for concern in the early stages.

On September 13, 2019, the FDA first announced that that NDMA was allegedly found in ranitidine-based medications.

They specifically mentioned Zantac as a name brand.

The FDA’s early investigations found that there was little more NDMA within Zantac than you would find in normal food intake or drinking water.

This was in comparison to a September 9, 2019, report by Valisure stating that Zantac may contain 3,000,000 nanagrams per capsule. The daily recommended max is 96 nanagrams per day.

Despite the FDA’s lower estimates, they still saw increasing need for action and issued a voluntary recall on all ranitidine-based medications on September 26, 2019.

Voluntary Recalls

A voluntary recall of Zantac meant that manufacturers should conduct their own experiments on their heartburn medications and make a recall if they found high levels of NDMA.

It also means that there was no recommendation at the time for people to quit taking their prescribed or OTC Zantac.

This voluntary recall resulted in a number of manufacturers pulling their medications from the markets.

Some of these manufacturers and repackagers included:

  • Sandoz Inc. – 9/24/2019
  • Dr. Reddy’s Laboratories Ltd – 10/23/2019
  • Sanofi – 10/23/2019
  • Perrigo Company plc – 10/28/2019
  • Novitium Pharma LLC – 10/28/2019
  • Lannett Company, Inc. – 10/28/2019
  • Aurobindo Pharma USA – 11/8/2019
  • Amneal – 11/12/2019
  • American Health Packaging – 11/12/2019
  • Golden State Medical Supply – 11/22/2019
  • Precision Dose Inc. – 11/22/2019
  • Glenmark Pharmaceutical Inc. – 12/18/2019
  • Mylan – 1/8/2020
  • Appco Pharma LLC – 1/8/2020
  • Northwind Pharmaceuticals – 1/8/2020
  • American Health Packaging – 2/27/2020
  • Amneal Pharmaceutical – 4/16/2020

Other Arising Information

On November 1, 2019, the FDA upheld that, based on their testing, the levels of NDMA found in Zantac were not much more than you would find in grilled or smoked meats.

The FDA also stated that some third-party scientists were using methods for testing that were not set out by the FDA, thus resulting in extremely high levels of NDMA in their findings.

Since the first recall, it was always given as an option that consumers could switch to alternative medications if they had concerns.

It wasn’t until the April 1, 2020, recall that the FDA actively recommended people stop taking all forms of ranitidine and talk with their doctors about alternative options.

The severity of a drug being taking off of shelves is large.

What started out as a simple statement from the FDA about slightly elevated levels of NDMA has now spiraled into a recall.

If you have a cancer diagnosis and have a prolonged history of Zantac usage, you can seek compensation.

Seeking Compensation in a Lawsuit

Cancer is a very serious diagnosis.

It is your right to seek compensation if you developed cancer after prolonged usage of Zantac or other ranitidine-based medications.

If you are considering filing a Zantac Lawsuit, you may wish to see if you pre-qualify for the mass tort litigation.

A mass tort simply means that a lot of other individuals are filing a similar lawsuit, have been diagnosed with major health issues after taking Zantac, and certain aspects of the case are dealt with in a more consistent manner by a federal judge.

You will still retain your right to seek out individual compensation.

Contact VanDerGinst Law

If you or a loved one has developed cancer or other serious health issue after taking Zantac or another ranitidine-based medication, the experienced and knowledgeable attorneys at VanDerGinst Law can help you obtain the compensation you deserve.

We encourage you to fill out our pre-qualification form to see if you may be eligible to file with us.

Or call VanDerGinst Law at 800-797-5391.

The law is tough, being injured is tougher.

We’ll make it easier for you.

The information contained on this website is presented by VanDerGinst Law P.C. It is not intended nor should it be construed as professional legal advice. The information is general in nature about the Firm, the scope of services we offer, and our community outreach, it is not legal advice. Please contact us by phone, email, mail, or via this website for inquiries. Contacting us does not create an attorney-client relationship. Please contact a personal injury attorney for a consultation regarding your situation. This website is not intended to solicit clients outside the State of Iowa and/or the State of Illinois.